



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/656,304	09/05/2003	Andrea M. McPhillips	02972938	8208

26565 7590 09/19/2008  
MAYER BROWN LLP  
P.O. BOX 2828  
CHICAGO, IL 60690

EXAMINER
----------

CLAYTOR, DEIRDRE RENEE

ART UNIT	PAPER NUMBER
----------	--------------

1617

NOTIFICATION DATE	DELIVERY MODE
-------------------	---------------

09/19/2008

ELECTRONIC

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ipdocket@mayerbrown.com

## Office Action Summary

Application No.

10/656,304

Applicant(s)

MCPHILLIPS ET AL.

Examiner

Renee Claytor

Art Unit

1617

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period **will** apply and **will** expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply **will**, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 29 July 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-10 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-10 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date: \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: \_\_\_\_\_.

## **DETAILED ACTION**

### ***Request for Continued Examination***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/29/2008 has been entered.

### ***Response to Arguments***

Applicant's restate that there is an objection the drawings but do not correct the drawings. The drawings need to be correct in the application. The original drawings filed on 9/5/2003 appear to be the drawings that correspond to the description of drawings listed in the specification. However, it is noted that this is not the set of drawings that are under examination. In response to a notice from the Office, Applicant's re-submitted replacement drawings on 4/29/2004 and also corrected drawings on 12/15/2006. These are not the same figures as what is described in the description of the drawings in the specification. The drawings need to be corrected the objection to the drawings is maintained.

Applicants argue over the 35 USC 103 rejection that Touitou is not obvious over the present invention because Touitou teaches embodiments that require a phospholipid. Applicants further argue that Touitou fails to provide guidance regarding

the development of the semiaqueous aerosol system of the present invention.

Applicants assert that Peart teaches away from using concentrations of ethanol larger than about 20% when administering THC to the lungs because the resulting droplet size would be too large to be effectively inhaled. Applicants point out that Vachon teaches a solvent system for aerosol delivery of THC comprising a ratio of propylene glycol to water of 9:1 which Applicants claim stand in contrast to the teachings of the present claims of propylene glycol being present in a range of 20-65%.

In response to the above arguments, it is noted that the present composition comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent comprising an alcohol, water and a glycol. It is noted that comprising language is considered to be open-ended and does not exclude additional, unrecited elements. See MPEP 2111.03. Therefore, the argument that Touitou requires a phospholipid in the composition of the invention is not persuasive because the present claims allow for the inclusion of additional components. The Examiner will suggest to the applicant to consider amending the claims to "consisting essentially of" language to limit the inclusion of other elements.

Regarding the arguments that Peart teaches away from using concentrations of ethanol larger than about 20%, it is noted that the specification of the present application does not limit ethanol concentrations to above 20% as the presently amended claims state. It is noted that in paragraph 0054 of the application, amounts varying from 10-70% are taught but there is no specific teaching in the specification limiting the solvent to amounts above 20%. There is no upper limit listed within the

claim; therefore, this claim limitation is considered new matter and is addressed below. Also, the argument about Vachon not teaching amounts of propylene glycol in the range of 20-65% as now presently claimed is not persuasive because as discussed above, there is no direct teaching in the specification of amounts of propylene glycol being present at less than 65% because there is no lower limit set in the claim. In particular, the specification teaches ranges from 20-80% of propylene glycol but makes no reference to amounts being less than 65%. Therefore, the new claims limitations are considered new matter. Applicants may want to consider putting ranges defining a limit in the claim, for example amending claim 1 to include 20-65% of the glycol and 20-70% of the alcohol.

### ***Claim Rejections – 35 USC 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1 and 6-7 rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. In the instant case, there is no direct teaching in the specification that the concentration of glycol is less than about 65%. The only teaching of the amounts of glycol in the specification are taught in ranges of between

20-80% but does not teach ranges below 20%. There is no indication of a preferred embodiment being less than about 65% without including a lower limit. Further, there is no direct teaching in the specification that the concentration of alcohol exceeds 20% of the composition. The specification teaches ranges of the alcohol between 10-70%. There is no indication of a preferred embodiment being more than 20% without an upper limit. Accordingly, the above is considered new matter.

***Claim Rejections – 35 U.S.C. § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-10 rejected under 35 U.S.C. 103(a) as being unpatentable over Touitou (U.S. Patent # 5,716,638) in view of Peart et al. (U.S. Patent # 6,509,005) and Vachon et al. (XP-000965573).

Touitou teaches a medical composition comprising ethanol (49%), water (29.4%), and propylene glycol (19.6%) in combination with tetrahydrocannabinol (THC; 7 µci/ml) as the active agent (see Table I), which encompasses claims 1-8.

Touitou fails to teach the dosage form of THC and an aerosol form of the composition.

Peart et al. teach a stable aerosol-dispensable pharmaceutical composition comprising a pharmaceutically effective concentration of delta-9-THC (Column 1, lines 20-27; claims), which is absorbed within seconds and delivered to the brain efficiently. Peart et al. also teach that an organic solvent such as ethanol can assist in solubilizing the delta-9-THC (Column 5, lines 50-52; claims). It is further taught that the optimal size of the respirable dose, or the mass of delta-9-THC in particles with aerodynamic diameters small enough to be delivered to and absorbed by the lungs, is less than 10  $\mu\text{m}$  in size (Column 6, lines 37-48), allowing for effective inhalation. A metered dose inhaler (MDI) is also taught for the aerosol administration of delta-9-THC.

Vachon et al. teach propylene glycol and water (in a ratio of 9:1) as a vehicle for holding THC (4.5 g/100ml) to be administered as an inhaled aerosol with a nebulizer (Materials, Methods and Subjects).

Furthermore, it is obvious to vary and/or optimize the mean mass median aerodynamic diameter provided in the composition, according to the guidance provided by Peart et al., to provide a composition having the desired properties such as the desired  $T_{\text{max}}$ . It is noted that “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955).

Accordingly, it would have been obvious to one skilled in the art at the time the invention was made to combine the teachings of Touitou and Peart and form a stable aerosolable composition with a pharmaceutically effective amount of delta-9-THC because Touitou teaches a composition comprised of ethanol, water, and propylene

glycol with delta-9-THC as the active ingredient and Peart teaches an aerosolable composition with a pharmaceutically effective amount of THC. Further it would have been obvious to one skilled in the art at the time the invention was made to further combine the teachings of Vachon who teaches that a vehicle of propylene glycol and water in a ratio of 9:1 is capable of holding up to 4.5 g of THC/100 ml in clear solution, with Touitou and Peart, because both teach THC as a therapeutic agent and a solvent comprising ethanol. To further address the limitation of a Tmax for delta-9-THC being achieved between 0.032 hour to about 0.041 hour, and in addressing the limitation of the Tmax for 11-OH-delta-9 tetrahydrocannabinol being achieved between about 0.115 hour to about 0.208 hour, both in claim 1, the Tmax for delta-9-THC and the Tmax for its metabolite 11-OH-delta-9 tetrahydrocannabinol would obviously be the same considering that the prior art teaches the same combination and the same mean mass median aerodynamic diameter.

One having ordinary skill in the art at the time the invention was made would have been motivated to employ the composition of Touitou in an aerosolable form of Peart et al. and Vachon et al., for more rapid onset of pharmacological action in the brain after administration of delta-9 THC. One having ordinary skill in the art at the time the invention was made would have been further motivated to employ the composition of Touitou in an aerosolable form of Peart et al. with delta-9 THC particles with aerodynamic diameters less than 10  $\mu\text{m}$  in size to allow for more effective inhalation and absorption by the lungs.



Claims 9-10 are rejected under 35 U.S.C. 103(a) as being unpatentable over Touitou (U.S. Patent # 5,716,638) in view of Peart et al. (U.S. Patent # 6,509,005) and Vachon et al. (XP-000965573) as applied to claims 1-8 above and further in view of LaMastro (U.S. Patent # 5,258,336).

Touitou, Peart et al., and Vachon et al. references are discussed above. Peart teaches administration of a composition via a metered dose inhaler (MDI) and Vachon teaches administration via a nebulizer.

Touitou, Peart et al., and Vachon et al. do not teach a sterile and/or preserved sealed unit-or multi-unit dosage form of delta-9 THC with Type I Amber Glass.

LaMastro et al. teach a Type I amber glass composition that provides a high degree of chemical stability and protection from ultraviolet light for certain pharmaceutical compositions (Column 1, lines 10-13).

Accordingly, it would have been obvious to one skilled in the art at the time the invention was made to combine the teachings of Touitou, Peart, and Vachon in further view of LaMastro to house the composition in a sterile and/or preserved sealed unit-or multi-unit dosage form of delta-9 THC in Type I amber glass. One having ordinary skill in the art at the time the invention was made would have been motivated to use Type I amber glass because it provides chemical stability and protection from ultraviolet light for pharmaceutical compositions.

### ***Conclusion***

No claims are allowed.

***Contact Information***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is (571)272-8394. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Renee Claytor

/SREENI PADMANABHAN/  
Supervisory Patent Examiner, Art Unit 1617